Continuous rocuronium infusion — Competitive Intelligence Brief

Continuous rocuronium infusion (Continuous rocuronium infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesia / Critical Care.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor (motor endplate) Anesthesia / Critical Care Small molecule

Target snapshot

Continuous rocuronium infusion (Continuous rocuronium infusion) — University Hospital, Antwerp. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continuous rocuronium infusion TARGET	Continuous rocuronium infusion	University Hospital, Antwerp	phase 3	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (motor endplate)
sufficient dose of rocuronium	sufficient dose of rocuronium	Korea University Guro Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
NMBA - cisatracurium	NMBA - cisatracurium	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent (NMBA)	Nicotinic acetylcholine receptor at the neuromuscular junction
Curare (Atracurium)	Curare (Atracurium)	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)
Rocuronium Injectable Solution	Rocuronium Injectable Solution	Federal University of São Paulo	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
NIMBEX	NIMBEX	Assistance Publique Hopitaux De Marseille	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Muscle Relaxant (Rocuronium)	Muscle Relaxant (Rocuronium)	Ostfold Hospital Trust	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class